Fedora Pharmaceuticals Inc. aims to head off bacterial growth with beta lactamase inhibitors that are effective against all classes of the antibiotic resistance-conferring enzyme. The Canadian startup hopes to advance one of its lead compounds into preclinical development by year end.

Beta lactamases are a diverse group of bacterial enzymes that degrade a variety of widely used antibiotics. The enzymes fall into four major classes - A, B, C and D - that vary considerably in their structure and biochemical characteristics, making it difficult to find a universally effective inhibitor.